Post hoc analysis of ARAMIS (1,509 patients with nmCRPC on ADT): metastatic progression occurred in 14% with darolutamide vs 29% with placebo, with similar sites. PSA <0.2 ng/ml was reached in 25.1% vs 0.5%, and reaching it was associated with less radiological progression.
Secondary analysisn = 1,509
Morgans et al. Disease progression patterns and association of prostate-specific antigen level with risk of progression in nonmetastatic castration-resistant prostate cancer